Analyst consensus rating
Acrivon Therapeutics Analyst Rating: none
Direct answer
Acrivon Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.50.
Forecast evidence checked September 5, 2026.
Get free Acrivon Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.13
- Average price target
- $11.50
- High price target
- $19.00
- Low price target
- $7.00
- Low target gap
- +228.6%
- Target upside
- +439.9%
- High target gap
- +792%
- Target range width
- 563.4%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Acrivon Therapeutics?
Acrivon Therapeutics has a verified none consensus. The same dataset has an average price target of $11.50.
How far are Acrivon Therapeutics's low and high targets from the recorded price?
The low target implies +228.6%, while the high target implies +792%.
How many analysts are included in Acrivon Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Acrivon Therapeutics's target upside or downside calculated?
The average target of $11.50 is divided by the recorded price of $2.13, then one is subtracted to produce +439.9%. This does not guarantee a future return.
When was Acrivon Therapeutics's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.